Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This onc...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Vitamin B12 and healthy aging are now linked by striking new evidence from Cornell University. A landmark study published in the Journal of...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

Diabetes type 2 treatment: Trial participants either underwent a procedure used to improve blood sugar control in type 2 diabetes called du...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...

Eli Lilly's Orforglipron, an anti-obesity pill, demonstrated significant weight loss and blood sugar reduction in clinical trials, rivaling...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participant...

Novo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.

"USFDA has endorsed company's plan to initiate a phase II clinical trial of Saroglitazar in patients with severe hypertriglyceridemia," Zyd...

Biocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3...

Piramal Life Sciences, the listed research and development (R&D) subsidiary of Piramal Healthcare, is hoping to hit the market with its fir...

This mkt being estimated to reach 1.5 bn by '10, which may trigger a shortage of around 30K to 50K clinical research professionals by then....

Nicholas Piramal to conduct this trial for the first time in the US for its breakthrough blood cancer drug.

Dr Reddy’s pursuit of past 13 years for the type 2 diabetes molecule is in its last lap, with the product entering the final phase of clini...

The stage has been set for the creation of the country’s first intellectual property in the pharma segment with Dr Reddy’s and Rheoscience ...